Overview
On 3 June 2008, orphan designation (EU/3/08/549) was granted by the European Commission to MolMed S.p.A, Italy, for NGR-human Tumour Necrosis Factor for the treatment of malignant mesothelioma.
Key facts
Active substance |
NGR-human tumour necrosis factor
|
Intended use |
Treatment of malignant mesothelioma
|
Orphan designation status |
Positive
|
EU designation number |
EU/3/08/549
|
Date of designation |
03/06/2008
|
Sponsor |
MolMed S.p.A.
Via Olgettina 58 20132 Milan Italy Telephone: +39 02 212 771 Telefax: +39 02 212 77 220 E-mail: info@molmed.com |
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: